A61K 47/6817
Toxins
Official title: {Toxins}
A61K47/6817 (Toxins) appears on 949 US grants and 1,347 published applications in this corpus.
Search patents in A61K- Granted patents
- 949
- Published applications
- 1,347
- Assignees
- 542
- Inventors
- 2,389
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 6 | 0 |
| 1983 | 5 | 0 |
| 1984 | 3 | 0 |
| 1985 | 2 | 0 |
| 1986 | 3 | 0 |
| 1987 | 6 | 0 |
| 1988 | 5 | 0 |
| 1989 | 7 | 0 |
| 1990 | 16 | 0 |
| 1991 | 5 | 0 |
| 1992 | 11 | 0 |
| 1993 | 6 | 0 |
| 1994 | 7 | 0 |
| 1995 | 5 | 0 |
| 1996 | 3 | 0 |
| 1997 | 15 | 0 |
| 1998 | 21 | 0 |
| 1999 | 20 | 0 |
| 2000 | 18 | 0 |
| 2001 | 9 | 1 |
| 2002 | 19 | 20 |
| 2003 | 18 | 25 |
| 2004 | 11 | 18 |
| 2005 | 8 | 21 |
| 2006 | 16 | 32 |
| 2007 | 5 | 18 |
| 2008 | 10 | 26 |
| 2009 | 13 | 36 |
| 2010 | 29 | 31 |
| 2011 | 16 | 45 |
| 2012 | 25 | 34 |
| 2013 | 20 | 43 |
| 2014 | 26 | 59 |
| 2015 | 41 | 57 |
| 2016 | 42 | 93 |
| 2017 | 54 | 88 |
| 2018 | 53 | 84 |
| 2019 | 45 | 77 |
| 2020 | 61 | 98 |
| 2021 | 51 | 90 |
| 2022 | 48 | 86 |
| 2023 | 50 | 101 |
| 2024 | 39 | 74 |
| 2025 | 46 | 52 |
| 2026 | 29 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- CD38 antibody drug conjugate15 Sep 2026US 12,734,209 B2Ogory, Inc.
- Compounds comprising a linker for increasing transcyclooctene stability25 Aug 2026US 12,714,752 B2Tagworks Pharmaceuticals B.V.
- Antibodies against human and canine IL-13RA225 Aug 2026US 12,715,926 B2Wake Forest University Health Sciences
- Nanobodies binding TROP2 and uses thereof25 Aug 2026US 12,715,931 B2Biosion Inc.
- Semicarbazone-based saponin conjugate18 Aug 2026US 12,708,638 B2Sapreme Technologies B.V.
- Fap-targeted antibody-drug conjugates8 Oct 2026US 2026/0306653 A1Oncomatryx Biopharma, S.L.
- Anti-psma antibodies and uses thereof8 Oct 2026US 2026/0308273 A1Bristol-Myers Squibb Company
- Enzymatic Removable Cell Penetration-Blocker (rCPB) Conjugated To A Tandem Peptide-Cytotoxin, Tandem Peptide-miRNA Chimeric Molecules Or Tandem Peptide-Antioncogenic miRNA For Targeted Cancer Cell Delivery, Off-Target Toxicity Minimization, Resistance Reduction, Gene Regulation, Anti-Tumor Immune Response Upregulation In The Tumor Microenvironment And Systemically, And Synergistic Enhancement Of Anti-Tumor Activity24 Sep 2026US 2026/0284217 A1
- Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives17 Sep 2026US 2026/0273017 A1Ambrx, Inc.
- Rabbit monoclonal antibodies targeting acute myeloid leukemia antigens10 Sep 2026US 2026/0265410 A1
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Therapeutic inhibitor of vascular smooth muscle cells562US 5,733,925 ANeoRx Corporation · 1998
- Solubilization of proteins for pharmaceutical compositions using polymer conjugation538US 4,766,106 ACetus Corporation · 1988
- Cysteine engineered antibodies and conjugates485US 7,521,541 B2Genetech, Inc. · 2009
- Recombinant production of immunoglobulin-like domains in prokaryotic cells477US 6,165,745 ABoard of Regents, The University of Texas System · 2000